Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rheonix Inc.

www.rheonix.com

Latest From Shenzhen Hepalink Pharmaceutical Co. Ltd.

Deal Watch: Novartis Signs Deals In Migraine & Diabetes

Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.

Deals M & A

Kymab Keeps Cash Coming In With $100m Led By Chinese Investors

UK biotech Kymab and its Kymouse platform has added $100m to its cash pile with a Series C financing led by Chinese investors. It plans to enter the clinic next year with its first antibody therapeutic for graft-versus-host disease (GvHD).

Commercial Financing

Curb Your Enthusiasm: Chinese Pharmas Going Global Hit Speed Bumps

Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.

Deals M & A

Latest R&D Deal Builds China Antibody Interest, Expertise

To promote both the development of innovative therapeutic antibodies from research originating in China and technology transfer, the Institute Pasteur of Shanghai and MRC Technology are collaborating to speed antibody R&D and scouting licensing opportunities with local pharmas, adding to a string of deals indicative of China’s increasing expertise and interest in the sector.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Biosensors
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Medical Devices
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rheonix Inc.
  • Senior Management
  • Tony Eisenhut, Pres. & CEO
    Peng Zhou, PhD, SVP, R&D & CSO
    Richard A Montagna, SVP, Corp. Bus. Dev. & Scientific Affairs
  • Contact Info
  • Rheonix Inc.
    Phone: (607) 257-1242
    22 Thornwood Dr.
    Ithaca, NY 14850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register